Display options
Cite
Inoue D, Yamamoto M, Sugita G, et al. Debulking surgery and hyperthermic intraperitoneal chemotherapy in the management of a recurrent aggressive uterine myxoid leiomyosarcoma with peritoneal dissemination. Gynecol Oncol Rep. 2015;13:60-3doi: 10.1016/j.gore.2015.06.010.
Inoue, D., Yamamoto, M., Sugita, G., Kurokawa, T., & Yoshida, Y. (2015). Debulking surgery and hyperthermic intraperitoneal chemotherapy in the management of a recurrent aggressive uterine myxoid leiomyosarcoma with peritoneal dissemination. Gynecologic oncology reports, 1360-3. https://doi.org/10.1016/j.gore.2015.06.010
Inoue, Daisuke, et al. "Debulking surgery and hyperthermic intraperitoneal chemotherapy in the management of a recurrent aggressive uterine myxoid leiomyosarcoma with peritoneal dissemination." Gynecologic oncology reports vol. 13 (2015): 60-3. doi: https://doi.org/10.1016/j.gore.2015.06.010
Inoue D, Yamamoto M, Sugita G, Kurokawa T, Yoshida Y. Debulking surgery and hyperthermic intraperitoneal chemotherapy in the management of a recurrent aggressive uterine myxoid leiomyosarcoma with peritoneal dissemination. Gynecol Oncol Rep. 2015 Jul 02;13:60-3. doi: 10.1016/j.gore.2015.06.010. eCollection 2015 Aug. PMID: 26425725; PMCID: PMC4563799.
Copy Download .nbib Format: NLM
Share it on

Gynecol Oncol Rep. 2015 Jul 02;13:60-3. doi: 10.1016/j.gore.2015.06.010. eCollection 2015 Aug.

Debulking surgery and hyperthermic intraperitoneal chemotherapy in the management of a recurrent aggressive uterine myxoid leiomyosarcoma with peritoneal dissemination.

Gynecologic oncology reports

Daisuke Inoue, Makoto Yamamoto, Genki Sugita, Tetsuji Kurokawa, Yoshio Yoshida

Affiliations

  1. Department of Obstetrics and Gynecology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.

PMID: 26425725 PMCID: PMC4563799 DOI: 10.1016/j.gore.2015.06.010

Abstract

•A rare case of recurrent peritoneal sarcomatosis (PS) arising from aggressive uterine myxoid leiomyosarcoma was described.•Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) has the potential to improve outcomes in PS from uterine sarcoma.•Careful patient selection for cytoreductive surgery with HIPEC is important to achieve better outcomes in PS.

Keywords: Advanced myxoid leiomyosarcoma; Hyperthermic intraperitoneal chemotherapy; Peritoneal sarcomatosis

References

  1. Oncol Rep. 2005 Jan;13(1):121-5 - PubMed
  2. Histopathology. 2011 Dec;59(6):1144-55 - PubMed
  3. Case Rep Obstet Gynecol. 2015;2015:316262 - PubMed
  4. Eur J Cancer. 1999 Mar;35(3):413-9 - PubMed
  5. Cancer. 2004 May 1;100(9):1943-50 - PubMed
  6. Ann Surg Oncol. 1999 Oct-Nov;6(7):645-50 - PubMed
  7. J Clin Oncol. 2009 Dec 20;27(36):6237-42 - PubMed
  8. Am J Obstet Gynecol. 2014 Mar;210(3):259.e1-8 - PubMed
  9. Ann Surg Oncol. 2007 Aug;14(8):2309-18 - PubMed
  10. Expert Rev Anticancer Ther. 2010 Feb;10(2):153-69 - PubMed
  11. Lancet Oncol. 2006 Jan;7(1):69-76 - PubMed
  12. Ann Surg Oncol. 2010 Dec;17(12):3220-8 - PubMed

Publication Types